VVUS - VIVUS, Inc.
| Previous Close | 3.9500 |
| Open | 3.9000 |
| Bid | 3.8800 x 1400 |
| Ask | 3.9000 x 4000 |
| Day's Range | 3.8700 - 3.9200 |
| 52 Week Range | 2.1500 - 5.7800 |
| Volume | 12,472 |
| Avg. Volume | 115,398 |
| Market Cap | 41.187M |
| Beta (3Y Monthly) | 2.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5960 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Zacks Small Cap Research
VVUS: Debt Reduced by ~$50 Million
By John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) announced the pay down of $48.6 million of its senior secured notes due 2024. The securities were yielding 10.375% and their early retirement is expected to save Vivus $10.5 million over the term of the loan. Vivus has held substantial cash on its balance sheet and now that they are close to operating free cash flow breakeven,
- GlobeNewswire
VIVUS Announces Acceptance of Qsymia Decentralized Marketing Authorization Application in Europe
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that European regulatory agencies in Sweden, Denmark, Finland, Iceland, Norway, and Poland (the “Concerned Member States”) have accepted the Marketing Authorization Application (the “MAA”) for Qsymia (phentermine and topiramate extended-release) on a decentralized basis, with Sweden acting as the lead Concerned Member State, also known as the Reference Member State, for purposes of assessing the MAA. Under the decentralized MAA procedure, the regulatory authorities in each of the Concerned Member States may simultaneously provide Marketing Authorization for use of a product within those specific countries.
- Simply Wall St.
How Much Are VIVUS, Inc. (NASDAQ:VVUS) Insiders Spending On Buying Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- GlobeNewswire
VIVUS Initiates Pay Down of Secured Debt and Announces Management Changes
-Reduction of $48.6 million of Secured Debt will result in total interest savings of $10.5 million--Organizational change streamlines commercial operations- CAMPBELL,.
- GlobeNewswire
VIVUS to Present at Upcoming Conferences
CAMPBELL, Calif., Aug. 28, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,.
- GlobeNewswire
VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
-Conference in Seoul provides opportunity to introduce an international audience to the clinical safety and benefits of Qsymia following its approval in the Republic of Korea-.
- Zacks Small Cap Research
VVUS: Qsymia Responds to New Approach
Vivus, Inc. (VVUS) released second quarter results on August 6, 2019 and provided an update of financial and operational results for the April to June period. During the three month interval the company achieved topline growth of 23%, launched online payments for Qsymia, assumed full responsibility for Pancreaze in Canada from Janssen and launched its Phase IV Qsymia study in adolescents. Following the end of the quarter, Vivus announced the approval of Qsymia in South Korea and disseminated results of a study illustrating the weight loss benefits of Qsymia used in conjunction with gastric sleeve surgery.
- Benzinga
A Look At Benzinga Pro's Most-Searched Tickers For August 21, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. iBio (NYSE: IBIO ) shares were down 14% to ...
- GlobeNewswire
New Pilot Clinical Study Results Demonstrate that Addition of VIVUS’ Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
“Patients with a BMI of 50 or greater generally benefit from bariatric surgery but have higher surgical risk and increased perioperative morbidity compared with patients with lower BMI,” said Jamy Ard, MD, Professor, Epidemiology and Prevention at Wake Forest School of Medicine and lead author on the publication. “In an effort to reduce these risks, we undertook a pilot study to assess the feasibility and impact of using the drug before and after LSG surgery. Study results show that patients taking it lost significantly more weight before surgery and had improved outcomes with respect to weight loss and BMI than those not on AOM.
- Thomson Reuters StreetEvents
Edited Transcript of VVUS earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Vivus Inc Earnings Call
- Simply Wall St.
Could The VIVUS, Inc. (NASDAQ:VVUS) Ownership Structure Tell Us Something Useful?
Every investor in VIVUS, Inc. (NASDAQ:VVUS) should be aware of the most powerful shareholder groups. Generally...
- GlobeNewswire
VIVUS Reports Second Quarter 2019 Financial Results.
CAMPBELL, Calif., Aug. 06, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
- GlobeNewswire
VIVUS Reports Second Quarter 2019 Financial Results
CAMPBELL, Calif., Aug. 06, 2019 -- VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty pharmaceutical company committed to the development and commercialization of.
- Zacks Small Cap Research
VVUS: Qsymia Receives Approval in Korea
The South Korean Ministry of Food and Drug Safety (MFDS) approved the drug as a safe and effective pharmaceutical. Vivus will receive a $2.5 million milestone from Alvogen as a result of the approval. Over the next several months, sales and marketing training will take place to prepare the salesforce to commercialize Qsymia.
- GlobeNewswire
VIVUS Announces Approval of Qsymia® in the Republic of Korea
VIVUS receives $2.5 million milestone payment CAMPBELL, Calif., Aug. 05, 2019 -- VIVUS, Inc. (Nasdaq:VVUS) (the “Company”), a biopharmaceutical company, announced today that.
- GlobeNewswire
VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
CAMPBELL, Calif., July 23, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the second quarter of 2019.
- GlobeNewswire
VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
VIVUS, Inc. (VVUS) (“VIVUS”), a biopharmaceutical company, today announced an amendment to its manufacturing and supply agreement with Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”) for PANCREAZE® (pancrelipase) Delayed Release Capsules. The amended agreement covers a ten-year initial term and may be renewed for additional five-year periods, the first at VIVUS’ option and by mutual agreement thereafter. Financial terms of the agreement were not disclosed. “As VIVUS continues its 10-quarter turnaround, ensuring PANCREAZE supply to meet the current and future demand for PANCREAZE at a stable and predictable price was a key step in our strategy, and we are pleased to have achieved this important milestone,” said John Amos, Chief Executive Officer at VIVUS.
- Simply Wall St.
Does The VIVUS, Inc. (NASDAQ:VVUS) Share Price Fall With The Market?
If you're interested in VIVUS, Inc. (NASDAQ:VVUS), then you might want to consider its beta (a measure of share price...
- GlobeNewswire
VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced the launch of an e-medicine platform that will enable patients with a prescription for Qsymia® (phentermine and topiramate extended-release) capsules CIV to purchase the medication online and have their orders delivered directly to their homes. The online ordering platform is another component of the Qsymia Advantage Program, which is designed to improve patient access to Qsymia. “One of the consistent pieces of feedback that we have heard from patients utilizing and physicians prescribing Qsymia has been the high out of pocket cost. Historically, the patient’s out of pocket cost has been in excess of $140 per month for the low strength doses and in excess of $200 per month for the high strength doses. These high out of pocket costs limited patients from initiating therapy or continuing therapy after initiation,” said John Amos, Chief Executive Officer at VIVUS.
- Zacks Small Cap Research
VVUS: Qsymia Receives an FDA Letter
On May 22nd, the FDA issued a letter to Vivus (VVUS) claiming that the company had made false or misleading claims and/or representations about the efficacy and risks of Qsymia. Based on observations by the Office of Prescription Drug Promotion (OPDP) of the FDA, it has found that the promotional material on the webpage violated the Federal Food, Drug and Cosmetic Act (FD&C Act) and is requesting that Vivus halt its violations. The OPDP requests that Vivus to submit a written response that the company intends to cease (remedy) the violations by June 7th, 2019, listing all promotional materials that include the cited violations along with a plan on how they discontinue their use.
- GlobeNewswire
VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
“Adolescent obesity represents one of the most critical medical and public health issues not only because one out of five teenagers is affected, but also due to the fact that medical treatment options are limited,” said Aaron Kelly, PhD, Associate Professor of Pediatrics, Co-Director of the Center for Pediatric Obesity Medicine at the University of Minnesota, and an investigator on the trial. “Childhood and adolescent obesity is known to impact both physical and psychological health, and increases the risks of adult obesity, type 2 diabetes and lipid disorders,” said Santosh T. Varghese, MD, Chief Medical Officer at VIVUS.
- GlobeNewswire
VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
CAMPBELL, Calif. and CHARLOTTE, N.C., May 15, 2019 -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, and HarborPath Direct, Inc., today announced a.
- Zacks Small Cap Research
VVUS: New Ideas for Established Portfolio
We are initiating coverage of VIVUS, Inc. (VVUS) with a $10.00 price target based on our revenue forecasts for approved products. In addition to a portfolio of weight loss, exocrine pancreatic insufficiency (EPI) and erectile dysfunction (ED) solutions, Vivus maintains a development program for pulmonary arterial hypertension (PAH). Existing product Qsymia and recently acquired product Pancreaze are expected to be the main revenue drivers over the next several years.
- Thomson Reuters StreetEvents
Edited Transcript of VVUS earnings conference call or presentation 30-Apr-19 8:30pm GMT
Q1 2019 Vivus Inc Earnings Call
- Associated Press
Vivus: 1Q Earnings Snapshot
On a per-share basis, the Campbell, California-based company said it had a loss of 75 cents. The biopharmaceutical company posted revenue of $16.1 million in the period. In the final minutes of trading ...
